Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-10-08

Clinical Trial Update: Xeljanz Special Investigation for Long-term Use in UC Patients

View source ↗

Summary

Pfizer's Xeljanz (tofacitinib) long-term-use study in ulcerative colitis has completed and results were posted on 2024-10-08.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Ulcerative Colitis | Status: COMPLETED | Results posted: 2024-10-08